arrow
N

Nadia Mazarakis

Murdoch Children's Research Institute
H指数:10
被引数:387

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial

分数剂量BNT162b2加强针在蒙古非mRNA基础免疫后诱导持久的免疫反应:一项随机对照试验

2026-03-270
OAAI
Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia

四价mRNA或蛋白质基COVID-19疫苗第四剂接种后12个月的免疫原性和效力:一项澳大利亚随机对照试验

2026-03-130
OA
Immunogenicity and Safety of Half and Full Doses of Heterologous and Homologous COVID-19 Vaccine Boosters After Priming with ChAdOx1 in Adult Participants in Indonesia: A Single-Blinded Randomized Controlled Trial

在印度尼西亚成年受试者中,以ChAdOx1为基础免疫后,异源和同源COVID-19疫苗加强针半剂量和全剂量的免疫原性和安全性:一项单盲随机对照试验

2025-11-150
OAAI
Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial

蒙古国成人中使用ChAdOx1-S、BBIBP-CorV或Gam-COVID-Vac进行基础免疫后,接受 fractional 和 standard 剂量的 BNT162b2 加强针在十二个月时的免疫原性和安全性:一项随机对照试验

Vaccine
IF3.5
2025-10-090
OAAI
Impaired IgM Memory B Cell Function Is Common in Coeliac Disease but Conjugate Pneumococcal Vaccination Induces Robust Protective Immunity

IgM记忆b细胞功能受损在乳糜泻中很常见,但结合肺炎球菌疫苗接种可诱导强大的保护性免疫

2024-02-191
OAAI
Immunogenicity, safety, and reactogenicity of a halfversus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial
2024-01-012
OAAI
Sulforaphane prevents and reverses allergic airways disease in mice via anti-inflammatory, antioxidant, and epigenetic mechanisms

莱菔硫烷通过抗炎、抗氧化和表观遗传机制预防和逆转小鼠过敏性气道疾病

2022-11-0110
PRE
Variants of Streptococcus pneumoniae Serotype 14 from Papua New Guinea with the Potential to Be Mistyped and Escape Vaccine-Induced Protection

来自巴布亚新几内亚的肺炎链球菌血清型14的变体可能被错误键入并逃避疫苗诱导的保护

2022-08-318
OAAI
Comparison of Seroconversion in Children and Adults With Mild COVID-19
2022-03-0960
OAAI